Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 15566

  • The following term was not found in PubMed: Fochon.
1.

Cortical-Bone Fragility - Insights from sFRP4 Deficiency in Pyle's Disease.

Simsek Kiper PO, Saito H, Gori F, Unger S, Hesse E, Yamana K, Kiviranta R, Solban N, Liu J, Brommage R, Boduroglu K, Bonafé L, Campos-Xavier B, Dikoglu E, Eastell R, Gossiel F, Harshman K, Nishimura G, Girisha KM, Stevenson BJ, Takita H, Rivolta C, Superti-Furga A, Baron R.

N Engl J Med. 2016 Jun 30;374(26):2553-2562.

PMID:
27355534
2.

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, Awan FT, Hexner E, Mauro MJ, Sternberg DW, Villeneuve M, Huntsman Labed A, Stanek EJ, Hartmann K, Horny HP, Valent P, Reiter A.

N Engl J Med. 2016 Jun 30;374(26):2530-2541.

PMID:
27355533
3.

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.

LaForce C, Feldman G, Spangenthal S, Eckert JH, Henley M, Patalano F, D'Andrea P.

Int J Chron Obstruct Pulmon Dis. 2016 Jun 8;11:1233-43. doi: 10.2147/COPD.S100445. eCollection 2016.

PMID:
27354782
4.

The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.

Erpenbeck VJ, Popov TA, Miller D, Weinstein SF, Spector S, Magnusson B, Osuntokun W, Goldsmith P, Weiss M, Beier J.

Pulm Pharmacol Ther. 2016 Jun 21. pii: S1094-5539(16)30044-X. doi: 10.1016/j.pupt.2016.06.005. [Epub ahead of print]

PMID:
27354118
5.

In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.

Charrier C, Salisbury AM, Savage VJ, Moyo E, Forward H, Ooi N, Cheung J, Metzger R, McGarry D, Walker R, Cooper IR, Ratcliffe AJ, Stokes NR.

J Antimicrob Chemother. 2016 Jun 26. pii: dkw228. [Epub ahead of print]

PMID:
27353465
6.

Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study.

Prasanna Kumar KM, Phadke U, Brath H, Gawai A, Paldánius PM, Mathieu C.

Prim Care Diabetes. 2016 Jun 25. pii: S1751-9918(16)30043-2. doi: 10.1016/j.pcd.2016.06.001. [Epub ahead of print]

PMID:
27353459
7.

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.

Lehmann C, Friess T, Birzele F, Kiialainen A, Dangl M.

J Hematol Oncol. 2016 Jun 28;9(1):50. doi: 10.1186/s13045-016-0280-3.

PMID:
27353420
8.

A new class of bifunctional major histocompatibility class I antibody fusion molecules to redirect CD8 T cells.

Schmittnaegel M, Hoffmann E, Imhof-Jung S, Fischer C, Drabner G, Georges G, Klein C, Knoetgen H.

Mol Cancer Ther. 2016 Jun 28. pii: molcanther.0207.2016. [Epub ahead of print]

PMID:
27353170
9.

Epratuzumab modulates B-cell signalling without affecting B-cell numbers or B- cell functions in a mouse model with humanised CD22.

Özgör L, Brandl C, Shock A, Nitschke L.

Eur J Immunol. 2016 Jun 29. doi: 10.1002/eji.201646383. [Epub ahead of print]

PMID:
27352780
10.

Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.

Groenendaal-van de Meent D, Adel MD, Noukens J, Rijnders S, Krebs-Brown A, Mateva L, Alexiev A, Schaddelee M.

Clin Drug Investig. 2016 Jun 28. [Epub ahead of print]

PMID:
27352308
11.

An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery.

Eriksson BI, Mikuska Z, Feuring M, Amiral J, Haertter S, Stangier J, Nehmiz G, Weitz JI.

Thromb Res. 2016 Jun 16;144:158-164. doi: 10.1016/j.thromres.2016.06.017. [Epub ahead of print]

PMID:
27352238
12.

A Novel Cost-Effectiveness Model of Prescription Eicosapentaenoic Acid Extrapolated to Secondary Prevention of Cardiovascular Diseases in the United States.

Philip S, Chowdhury S, Nelson JR, Everett PB, Hulme-Lowe CK, Schmier JK.

J Med Econ. 2016 Jun 28:1-22. [Epub ahead of print]

PMID:
27352086
13.

Creation new patient information leaflets with diabetes by pharmacists and assesment conducted by patients.

Arai M, Maeda K, Satoh H, Miki A, Sawada Y.

Yakugaku Zasshi. 2016 Jun 27. [Epub ahead of print]

PMID:
27350717
14.

Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives.

Groen-Wijnberg M, van Dijk J, Krauwinkel W, Kerbusch V, Meijer J, Tretter R, Zhang W, van Gelderen M.

Eur J Drug Metab Pharmacokinet. 2016 Jun 28. [Epub ahead of print]

PMID:
27350625
15.

A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.

Mross K, Richly H, Frost A, Scharr D, Nokay B, Graeser R, Lee C, Hilbert J, Goeldner RG, Fietz O, Scheulen ME.

Cancer Chemother Pharmacol. 2016 Jun 27. [Epub ahead of print]

PMID:
27349901
16.

Towards the development of a paediatric biopharmaceutics classification system: Results of a survey of experts.

Batchelor H, Ernest T, Flanagan T, Klein S, Turner R, Fotaki N, Storey D; EuPFI.

Int J Pharm. 2016 Jun 24. pii: S0378-5173(16)30605-6. doi: 10.1016/j.ijpharm.2016.06.115. [Epub ahead of print]

PMID:
27349792
17.

Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls.

Dib J, Mongongu C, Buisson C, Molina A, Schänzer W, Thuss U, Thevis M.

Drug Test Anal. 2016 Jun 27. doi: 10.1002/dta.2011. [Epub ahead of print]

PMID:
27346747
18.

Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus.

Stockis A, Hartstra J, Mollet M, Hadi S.

Epilepsia. 2016 Jun 26. doi: 10.1111/epi.13433. [Epub ahead of print]

PMID:
27346728
19.

Cytoplasmic aggregates of dynactin in iPSC-derived tyrosine hydroxylase-positive neurons from a patient with Perry syndrome.

Mishima T, Ishikawa T, Imamura K, Kondo T, Koshiba Y, Takahashi R, Takahashi J, Watanabe A, Fujii N, Tsuboi Y, Inoue H.

Parkinsonism Relat Disord. 2016 Jun 15. pii: S1353-8020(16)30226-7. doi: 10.1016/j.parkreldis.2016.06.007. [Epub ahead of print]

PMID:
27346608
20.

Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research.

Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AF, Barch DM, Bearden CE, Braff DL, Brown ES, Bullmore ET, Carlezon WA Jr, Carter CS, Cook EH Jr, Daskalakis ZJ, DiLeone RJ, Duman RS, Grace AA, Hariri AR, Harrison PJ, Hiroi N, Kenny PJ, Kleinman JE, Krystal AD, Lewis DA, Lipska BK, Marder SR, Mason GF, Mathalon DH, McClung CA, McDougle CJ, McIntosh AM, McMahon FJ, Mirnics K, Monteggia LM, Narendran R, Nestler EJ, Neumeister A, O'Donovan MC, Öngür D, Pariante CM, Paulus MP, Pearlson G, Phillips ML, Pine DS, Pizzagalli DA, Pletnikov MV, Ragland JD, Rapoport JL, Ressler KJ, Russo SJ, Sanacora G, Sawa A, Schatzberg AF, Shaham Y, Shamay-Tsoory SG, Sklar P, State MW, Stein MB, Strakowski SM, Taylor SF, Turecki G, Turetsky BI, Weissman MM, Zachariou V, Zarate CA Jr, Zubieta JK.

Biol Psychiatry. 2016 Jul 15;80(2):84-6. doi: 10.1016/j.biopsych.2016.05.004. No abstract available.

PMID:
27346079
Items per page

Supplemental Content

Loading ...
Write to the Help Desk